EGFR and non-small cell lung carcinoma: However, the mechanism through which EGFR activation influences PD-L1 expression and the potential role of blocking PD-1/PD-L1 in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) are largely unknown [25].